- Home
- SI vs CLLS Comparison
SI vs CLLS Comparison
Compare SI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | CLLS |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 394.4M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SI | CLLS |
|---|---|---|
| Price | $18.18 | $0.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $26.50 | $4.83 |
| AVG Volume (30 Days) | ★ 98.4K | 73.6K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,317,000.00 | N/A |
| Revenue This Year | $44.61 | N/A |
| Revenue Next Year | $29.19 | $10.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.63 | N/A |
| 52 Week Low | $10.92 | $1.03 |
| 52 Week High | $24.60 | $5.45 |
Technical Indicators
Market Signals| Indicator | SI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 16.89 |
| Support Level | $17.69 | N/A |
| Resistance Level | $20.03 | $2.99 |
| Average True Range (ATR) | 0.91 | 0.08 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 36.18 | 3.11 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.